News | May 30, 2026
The bonds, due June 15, 2030, were placed with Swiss investors under the joint lead of UBS and Zürcher Kantonalbank
The company said the breadth of its showcase reflects “progress from its differentiated oncology pipeline in solid tumors and hematologic malignancies,”
The development comes as stroke remains one of the world’s biggest health threats
Highlighting KEYTRUDA & expanding cancer pipeline
Successful inspection outcome strengthens company’s regulatory compliance and manufacturing standards in China
Lifts full-year outlook as obesity drug boom accelerates
Health innovations are viewed more positively than food and agricultural technologies
With big pharma leaning on external pipelines, the company sees opportunity in de-risked, high-impact assets with clear clinical endpoints
On the generics and biosimilars front, the combined business is expected to benefit from Sun’s portfolio of more than 550 approved ANDAs across multiple dosage forms
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
